Low human beta-defensin-2 levels in the sputum of COPD patients are associated with the risk of exacerbations

Chronic obstructive pulmonary disease (COPD) is a complicated chronic inflammatory disease. It is important to investigate the characteristics of acute exacerbation of COPD to develop new therapeutic strategies. This study aimed to determine the relationship between the human beta-defensin-2 (hBD-2)...

Full description

Saved in:

Bibliographic Details
Published in:	BMC pulmonary medicine 2023-03, Vol.23 (1), p.106-106, Article 106
Main Authors:	Feng, Shengchuan, Yang, Yuqiong, Wang, Fengyan, Shi, Weijuan, Xu, Jiaxuan, Tang, Guoyan, Xie, Jiaxing, Zhong, Nanshan, Liang, Zhenyu, Chen, Rongchang
Format:	Article
Language:	eng
Subjects:	Adult Aged Bacteria Bacterial infections beta-Defensins - therapeutic use Care and treatment Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) Connectivity CXCL10 protein CXCL11 protein Cytokines Defensins Exacerbations hBD-2 Health aspects Humans Inflammatory diseases Kidney diseases Liver diseases Lung diseases Lung diseases, Obstructive Metabolic disorders Microbial colonization Microorganisms Middle Aged Musculoskeletal diseases Obstructive lung disease Patient outcomes Peptides Pulmonary Disease, Chronic Obstructive Pulmonology Questionnaires Sputum Sputum - microbiology Statistical analysis Streptococcus infections Viral infections Viruses
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Chronic obstructive pulmonary disease (COPD) is a complicated chronic inflammatory disease. It is important to investigate the characteristics of acute exacerbation of COPD to develop new therapeutic strategies. This study aimed to determine the relationship between the human beta-defensin-2 (hBD-2) levels and aggravation of COPD. We detected the sputum hBD-2 level of 254 patients from Guangzhou, China, for 2 years. The study participants were categorized into the COPD group (n = 203, GOLD 0-4) and the control group (n = 51, 40-79 years old). At baseline, 12th month, and 24th month, we detected the sputum hBD-2 level and levels of cytokines, such as CXCL10, CXCL11, and IFN. At baseline, there were no significant differences in the sputum and serum hBD-2 levels between the patients and the controls. However, the sputum hBD-2 levels of patients who had at least one symptom aggravation over the next 2 years were significantly lower than those of patients without any exacerbations (1130.9 ± 858.4 pg/mL vs. 2103.7 ± 1294.2 pg/mL, respectively; p = 0.001). Nevertheless, there were no statistically significant differences in the sputum hBD-2 levels between patients (no aggravation history) and controls (2084.9 ± 1317.6 pg/mL vs. 2152.5 ± 1251.6 pg/mL, respectively; p = 0.626). We used a logistic regression model to assess the relationship between aggravation and sputum hBD-2 levels. Interestingly, we found that low hBD-2 level (
ISSN:	1471-2466 1471-2466